Drug intelligence / Profile preview

tetanus toxoid vaccine adsorbed

Development stage
Approved
Lead developer
Sanofi Pasteur
Modality
Vaccines & Immunotherapeutics
Administration
Intramuscular
01

Overview

**Tetanus toxoid vaccine adsorbed** is a sterile, cloudy, whitish suspension used for intramuscular injection to provide active immunization against tetanus in individuals seven years and older[3][5]. The vaccine is manufactured by growing *Clostridium tetani* in a suitable medium and detoxifying the toxin with formaldehyde to produce tetanus toxoid, which is then adsorbed onto an aluminum salt adjuvant (such as aluminum phosphate or aluminum potassium sulfate)[1][3]. Upon administration, the vaccine stimulates the immune system to produce antibodies against the tetanus toxin, conferring protective immunity. Some products combined tetanus toxoid with diphtheria toxoid (e.g., Td ADSORBED, TDVAX, TENIVAC), but some are solely tetanus toxoid adsorbed preparations[1][3][4]. The vaccine does not provide protection against other diseases and is not effective for the treatment of established tetanus.

Brand names
Td ADSORBEDTDVAXTENIVAC
Other names
tetanus toxoid adsorbedtetanus and diphtheria toxoids adsorbedtetanus toxoid vaccine adsorbed

Beyond the preview

Go deeper on tetanus toxoid vaccine adsorbed.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on tetanus toxoid vaccine adsorbed.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call